Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.62 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.42 |
| ▸ | CCKAR | P32238 | 5/20 | 0.41 |
| ▸ | CCKBR | P32239 | 5/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18885578 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL15369019 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL2373708 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL21242756 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL23081524 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL18885624 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL24899308 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL22245502 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL25454272 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL22245528 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2637698-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2022-04-20 | — | — | EP | claimed |
| EP-2820038-B1 | GLP-1 PRODRUGS | NOVO NORDISK AS (DK) | 2020-06-17 | — | — | EP | claimed |
| EP-2513141-B1 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK AS (DK) | 2017-03-01 | — | — | EP | claimed |
| EP-2552950-A1 | NOVEL GLUCAGON ANALOGUES | Novo Nordisk A/S (DK) | 2013-02-06 | — | — | EP | claimed |
| WO-2011117415-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2011-09-29 | — | — | WO | claimed |
| US-20230103631-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | SANOFI (FR) | 2023-04-06 | — | — | US | disclosed |
| US-20220251535-A1 | AMINOACYL-TRNA SYNTHETASES AND USES HEREOF | NOVO NORDISK A/S (DK) | 2022-08-11 | — | — | US | disclosed |
| EP-2637698-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2022-04-20 | — | — | EP | disclosed |
| US-20220017589-A1 | FUSION PROTEINS OF GLP-1 AND GDF15 AND CONJUGATES THEREOF | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| US-11130794-B2 | Bifunctional compounds | NOVO NORDISK A/S (DK) | 2021-09-28 | — | — | US | disclosed |
| US-20200231645-A1 | Bifunctional compounds | NOVO NORDISK A/S (DK) | 2020-07-23 | — | — | US | disclosed |
| WO-2020143625-A1 | NOVEL POLYPEPTIDE AND THERAPEUTIC USES THEREOF | 鸿绪生物医药科技（北京）有限公司 | 2020-07-16 | — | — | WO | disclosed |
| US-20130053311-A1 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-02-28 | — | — | US | disclosed |
| EP-2552950-A1 | NOVEL GLUCAGON ANALOGUES | Novo Nordisk A/S (DK) | 2013-02-06 | — | — | EP | disclosed |
| EP-2513141-A2 | GLP-1 ANALOGUES AND DERIVATIVES | Novo Nordisk A/S (DK) | 2012-10-24 | — | — | EP | disclosed |
| EP-2512518-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS | Novo Nordisk A/S (DK) | 2012-10-24 | — | — | EP | disclosed |
| WO-2012062803-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2012-05-18 | — | — | WO | disclosed |
| WO-2011117415-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011080102-A2 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK A/S (DK) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011073328-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS | NOVO NORDISK A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017589-A1 | FUSION PROTEINS OF GLP-1 AND GDF15 AND CONJUGATES THEREOF | GLP1R, IAPP, GIPR | GLP1R 1/4885NOD1 462/4885CCKAR 36/4885 |
| US-11130794-B2 | Bifunctional compounds | GLP1R, PCSK9, PCSK7 | GLP1R 1/4885NOD1 743/4885CCKAR 26/4885 |
| US-20130053311-A1 | GLP-1 ANALOGUES AND DERIVATIVES | GLP1R, IAPP, SLC5A1 | GLP1R 1/4885NOD1 221/4885CCKAR 216/4885 |
| US-20230103631-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | GIPR, GLP1R, GPR119 | GLP1R 2/4885NOD1 2211/4885CCKAR 31/4885 |
| US-20200231645-A1 | Bifunctional compounds | GLP1R, PCSK9, PCSK7 | GLP1R 1/4885NOD1 743/4885CCKAR 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.